Antithrombotic pharmacotherapy

Antithrombotic Pharmacotherapy for Patients With Various Diseases... 

Deborah DeEugenio, Pharm.D., B.C.P.S., is a 2001 graduate of the Philadelphia College of Pharmacy at the University of the Sciences (Philadelphia). She completed a residency in Pharmacy Practice at Thomas Jefferson University Hospital (Philadelphia). Dr. DeEugenio is a member of the Temple University School of Pharmacy faculty as a Clinical Assistant Professor and a Certified Antithrombotic Provider and a Board Certified Pharmacotherapy Specialist. Her clinical activity takes place at Jefferson Heart Institute as part of the Jefferson Antithrombotics Therapy Service. The ambulatory clinic serves 400 patients on chronic anticoagulation therapy and provides continuous monitoring and education to these patients. The clinic also provides drug information and pharmacy support to the physicians and other health-care providers at the Institute. 

Deborah DeEugenio holds a Doctor of Pharmacy degree from the University of the Sciences in Philadelphia, Philadelphia College of Pharmacy. She completed a post- doctoral residency in pharmacy practice at Thomas Jefferson University Hospital. Dr. DeEugenio is a Board Certified Pharmacotherapy Specialist and a Certified Anticoagulation Provider. Dr. DeEugenio is currently an Assistant Professor at Temple University School of Pharmacy in Philadelphia. She also works at Thomas Jefferson University Hospital as a clinical pharmacist for Jefferson Heart Institute and Jefferson Antithrombotics Therapy Service. 

Adjunctive pharmacotherapy is an essential aspect of percutaneous coronary intervention. Optimization of both antithrombotic and antiplatelet therapies... 

More than 90% of patients achieve TIMI 3 flow with primary PCI (17,18) however, normal myocardial perfusion was attained in only -30% of patients despite TIMI 3 flow (19). Similar to thrombolytic therapy, the presence of normal epicardial and myocardial perfusion was associated with the best clinical outcomes. Among patients for whom TIMI 3 flow was restored, 1-year survival was 6.8% in the presence of normal myocardial blush, 13.2% with reduced myocardial blush, and 18.3% with absent myocardial blush (p = 0.0004) (Fig. 6.6) (19). Therefore, adjunctive aggressive pharmacotherapy (antiplatelet, antithrombotic, and fibrinolytic therapies) that could improve myocardial perfusion, further supplementing mechanical revascularization, will provide additive benefit to patients with STEMI. Furthermore, there is often a time delay from the door to balloon, which, compounded... 

---